Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
暂无分享,去创建一个
[1] B. Szwergold,et al. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. , 1999, Diabetes.
[2] R. Bouillon,et al. Diabetic bone disease , 2007, Calcified Tissue International.
[3] P. Vestergaard,et al. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk , 2005, Diabetologia.
[4] G. Stein,et al. Advanced glycation end-products pentosidine and N " -carboxymethyllysine are elevated in serum of patients with osteoporosis , 2003 .
[5] S. Yamagishi,et al. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo. , 2004, Medical hypotheses.
[6] C. Cooper,et al. Diagnosis and epidemiology of osteoporosis , 2005, Current opinion in rheumatology.
[7] M. Kayath,et al. Prospective bone mineral density evaluation in patients with insulin-dependent diabetes mellitus. , 1998, Journal of diabetes and its complications.
[8] S. Edelman,et al. Osteoporosis and Diabetes , 2002, Current diabetes reports.
[9] R. Bucala,et al. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[10] T. Imaizumi,et al. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. , 2003, International journal of clinical pharmacology research.
[11] A. Folsom,et al. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. , 2001, Diabetes care.
[12] Z. Makita,et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. , 2002, Biochemical and biophysical research communications.
[13] A. Schwartz,et al. Diabetes Mellitus: Does it Affect Bone? , 2003, Calcified Tissue International.
[14] L. Parsons. Osteoporosis: incidence, prevention, and treatment of the silent killer. , 2005, The Nursing clinics of North America.
[15] S. Yamagishi,et al. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. , 2004, Drugs under experimental and clinical research.
[16] A. Schmidt,et al. Atherosclerosis and diabetes: The rage connection , 2000, Current atherosclerosis reports.
[17] R. Ziegler,et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.
[18] A. Jenkins,et al. Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.
[19] S. Yamagishi,et al. TAGE (toxic AGEs) hypothesis in various chronic diseases. , 2004, Medical hypotheses.
[20] Hiroshi Yamamoto,et al. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells , 1998, Diabetologia.
[21] S. Kato,et al. Advanced Glycation End‐Products Attenuate Human Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, Cartilage, and Bone , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] T. Miyata,et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. , 1997, Journal of the American Society of Nephrology : JASN.